HECTOR.
Trial name or title | Topotecan plus carboplatin (TC) versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): a randomised phase III trial of the NOGGO‐AGO‐Germany‐AGO Austria and GEICO‐GCIG intergroup study (HECTOR) |
Methods | Phase III multicentre RCT |
Participants | 550 women with PS ROC. |
Interventions | Arm 1:TC Arm 2: GC or PC or PLDC |
Outcomes | Primary: PFS Secondary: toxicity |
Starting date | Accrual from Feb 2007 to Dec 2009 |
Contact information | Sehouli@aol.com |
Notes | Interim data of the first 200 women were presented at ASCO 2012. However, approx. 78% of control arm received GC and it is not clear how many participants, if any, received the PLDC intervention. We emailed the lead investigator for more information on 13/11/12 and 30/11/12. |